Skip to main content

Advertisement

Fig. 6 | Breast Cancer Research

Fig. 6

From: Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Fig. 6

Depressed anti-human epidermal growth factor receptor 2 (anti-HER2) T-helper type-1 (Th1) immunity is restored following HER2-pulsed type 1-polarized dendritic cell (DC1) immunization. a Anti-HER2 CD4+ T cell immune reactivity profiles in four patients with non-pCR (UPCC # 26113–01 to −04) undergoing HER2-pulsed DC1 vaccination in the ongoing phase I trial NCT02061423 are demonstrated at three time points: pre-vaccination (black), 3 months post vaccination (gray), and 6 months post vaccination (white). For these time points, responses to individual HER2-derived class II peptides (x-axis; p42, p98, p328, p776, p927, p1166) are graphed, with anti-CD3/CD28 serving as positive control. Anti-HER2 Th1 repertoire and cumulative responses at these time points are listed in adjoining tables. b Anti-HER2 Th1 repertoire (mean # of reactive peptides) and cumulative response (mean total SFC/10 6 cells) increase progressively in patients with non-pCR at the 3-month and 6-month time points. SFC spot-forming cells

Back to article page